# INOGENIX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inogenix

- Industry: Medical Devices & Equipment
- Headquarters: Chuncheon-si, South Korea
- Website: www.inogenix.com/
- Latest round: Seed (Oct 25, 2021)
- Investors on record: 1

## About

Based in South Korea, INOGENIX specializes in molecular diagnostics, delivering innovative medical devices aimed at addressing critical clinical needs. The company focuses on enhancing patient outcomes through precise diagnostic solutions.

Founded in 2019 and headquartered in Chuncheon-si, South Korea, INOGENIX operates in the field of molecular diagnostics. The company is led by Hye-young Lee, who serves as both the Founder and CEO. INOGENIX has made two notable investment deals, with the most recent transaction occurring on May 12, 2026 which involved raising KRW 4.5 billion in venture funding from new investors Korea Asset Investment Capital, KOLON PHARMA, Yonsei Biohealth Technology Holdings, and Ewha Technology Holdings. 

INOGENIX Inc. specializes in molecular diagnostics, delivering a range of innovative medical devices designed to address unmet clinical needs. Their core product offerings include the Atopy Prediction Service (AGA), Colorectal Cancer Test, INO MTB-Alive Detection, and COVID-19 testing solutions. These products leverage artificial intelligence to provide personalized medical services, aiming to enhance patient outcomes through precise diagnostics. The company primarily serves healthcare institutions, laboratories, and clinical practitioners, focusing on regions with high demand for advanced diagnostic tools, including North America and parts of Asia. By providing these solutions, INOGENIX aims to improve the quality of healthcare and patient well-being.

INOGENIX operates through a business model that involves direct transactions with healthcare providers and laboratories, facilitating the delivery of their diagnostic products and services. The company’s revenue streams are derived from the sale of individual testing kits and subscription services for ongoing access to their diagnostic platforms. Healthcare institutions may engage in contractual agreements, wherein they purchase testing kits for various applications, such as cancer detection or infectious disease diagnostics. This structure suggests a focus on B2B relationships, catering to hospitals and specialty clinics that require advanced molecular testing.

The company will use the May 2026 funding to expedite its clinical trials and regulatory certification.

## Funding rounds

- Seed, Oct 25, 2021 — Krypton

## Investors

- Krypton (https://capitalatlas.ai/funds/krypton) — Seed